Rely on one prefilled syringe (PFS) flu vaccine to cover all recommended ages1,2

  6 months-35 months* 36 months and older *
FLULAVAL QUADRIVALENT1 0.5-mL
Fluzone Quadrivalent4 0.25-mL 0.5-mL
dosing_syringe_graphic

Administering FLULAVAL QUADRIVALENT

  • The preferred sites for intramuscular injection are the anterolateral thigh for children aged 6 through 11 months and the deltoid muscle of the upper arm for persons aged 12 months and older1
  • Do not administer this product intravenously, intradermally, or subcutaneously1
dosing_thermometer_graphic

Storing FLULAVAL QUADRIVALENT

  • FLULAVAL QUADRIVALENT should be refrigerated between 36°F and 46°F (2°C-8°C). Do not freeze1
  • Once entered, multi-dose vials should be discarded after 28 days1
dosing_key_graphic

Key facts about vaccination errors

  • According to the Vaccine Adverse Event Reporting System (VAERS), the wrong vaccine being administered is one of the most common vaccination errors reported5,†
  • In a recent Institute for Safe Medication Practices (ISMP) report, of the flu vaccine administration errors submitted to the ISMP, administration of a vaccine not indicated for the patient's age group is the most common6,‡
dosing_bandaid_graphic

With FLULAVAL QUADRIVALENT, you can vaccinate all recommended patients (6 months +) with the same dose (0.5-mL)1,2

Please note that there are no data demonstrating that the use of FLULAVAL QUADRIVALENT reduces administration errors.

* One or 2 doses, depending on vaccination history, per the annual Advisory Committee on Immunization Practices recommendations on prevention and control of influenza with vaccines. If 2 doses, administer each dose at least 4 weeks apart. Patients aged 9 years and older receive only 1 dose, regardless of vaccination history.1,4
Reported years 2000-2013. N (total errors reported)=21,843.5
Institute for Safe Medication Practices National Vaccine Errors Reporting Program.

Nurse’s Guide to FLULAVAL QUADRIVALENT

FLULAVAL is a registered trademark of the GSK group of companies.
Fluzone is a registered trademark of Sanofi Pasteur Inc.

Indication

FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older.

Important Safety Information for FLULAVAL QUADRIVALENT

  • Do not administer FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients

Please see full Prescribing Information for FLULAVAL QUADRIVALENT.

View all references.

 

819254R0 September 2017